<DOC>
	<DOCNO>NCT01248364</DOCNO>
	<brief_summary>An open-label , phase II study ass acute chronic effect empagliflozin ( BI 10773 ) fast postprandial glucose homeostasis patient IGT type 2 diabetes mellitus assess acute effect empagliflozin healthy subject .</brief_summary>
	<brief_title>A Study Determine Acute ( After First Dose ) Chronic ( After 28 Days ) Effects Empagliflozin ( BI 10773 ) Pre Postprandial Glucose Homeostasis Patients With Impaired Glucose Tolerance Type 2 Diabetes Mellitus Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient diagnose IGT accord current ADA guideline twohour glucose level 140 199 mg/dl ( 7.8 mmol/l 11.1 mmol/l ) 75g oral glucose tolerance test ( OGTT ) , OGTT perform time screen visit ( Visit 1 ) , ¿ Male female patient diagnose type 2 diabetes mellitus ( T2DM ) prior inform consent , diet exercise regimen drugnaïve , define absence oral antihyperglycemic therapy 12 week prior start openlabel active treatment , 2 . Male female patient diagnose type 2 diabetes mellitus prior inform consent , pretreated metformin background therapy , stable dose metformin least 1500 mg per day , unchanged least 12 week prior start openlabel active treatment 3 . HbA1c Visit 1 ( screen ) 1. patient diagnosed IGT healthy subject : HbA1c &lt; 6.5 % 2. patient diagnosed T2DM : HbA1c =6.5 % =10.5 % 4 . Age = 18 Visit 1 5 . BMI = 20 = 40 Kg/m2 Visit 1 6 . For patient antihypertensive treatment , must stable ( change dosage ) within 4 week prior start openlabel active treatment 7 . Signed date write informed consent date Visit 1 accordance GCP local legislation Inclusion criterion healthy subject : 8 . Males females match mention criterion otherwise healthy accord investigator¿s assessment , base follow criterion : complete medical history include physical examination , vital sign ( BP , PR ) clinical laboratory test . 9 . HbA1c Visit 1 ( screen ) : HbA1c &lt; 6.5 % 10 . Confirmed normal glucose tolerance ( NGT ) OGTT 11 . Age = 45 = 55 Visit 1 . 12 . BMI = 30 = 40 Kg/m2 ( Body Mass Index ) Visit 1 . 13 . Signed date write informed consent date Visit 1 accordance GCP local legislation . Exclusion criterion : 1 . Acute coronary syndrome ( nonSTEMI [ ST elevation myocardial infarction ] , STEMI , unstable AP [ angina pectoris ] ) , stroke Transient Ischemic Attack ( TIA ) within 6 month prior inform consent . 2 . Uncontrolled hyperglycaemia glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) overnight fast placebo runin confirm second measurement ( day ) . 3 . Any antidiabetic drug within 12 week prior start openlabel active treatment ( Visit 4 ) except define background via inclusion criterion 1c . 4 . Indication liver disease , define serum level either Alanine Aminotransferase ( ALT [ SGPT ] ) , Aspartate Aminotransferase ( AST [ SGOT ] ) , alkaline phosphatase 3 x upper limit normal ( ULN ) determine screen and/or runin phase . 5 . Impaired renal function , define estimate Glomerular Filtration Rate ( eGFR ) &lt; 60 ml/min ( moderate severe renal impairment ) determine screen and/or runin phase . 6 . Medical history insufficient bladder emptying ( i.e . neurogenic bladder disorder ) . 7 . Patients Haemoglobin ( Hb ) &lt; 11.5 g/dl ( male ) Hb &lt; 10.5 g/dl ( female ) Visit 1 . 8 . Bariatric surgery within past two year gastrointestinal surgery induce chronic malabsorption within last 5 year . 9 . Medical history cancer ( except basal cell carcinoma ) and/or treatment cancer within last 5 year . 10 . For patient metformin background therapy , investigator must check potential exclusion criterion accord local metformin label . 11 . Treatment antiobesity drug 3 month prior inform consent treatment time screen ( i.e . surgery , aggressive diet regimen , etc . ) lead unstable body weight . 12 . Current treatment systemic steroid time informed consent change dosage thyroid hormone within 6 week prior inform consent uncontrolled endocrine disorder except T2DM . However , use inhaled steroid ( e.g. , asthma , Chronic Obstructive Pulmonary Disease [ COPD ] ) exclusion cause systemic steroid action . 13 . Alcohol drug abuse ( accord investigator judgment ) within 3 month prior inform consent would interfere trial participation ongoing condition lead decrease compliance study procedure study drug intake . 14 . Intake investigational drug another trial Participation another trial within 30 day prior intake study medication trial . 15 . Premenopausal woman ( last menstruation &lt; = 1 year prior informed consent ) : Are nurse pregnant Are childbearing potential practicing acceptable method birth control , plan continue use method throughout study agree submit periodic pregnancy test participation trial . 16 . Any clinical condition would jeopardize patient safety participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>